Comparing two doses of albumin for cirrhosis patients with SBP
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether a lower dose of albumin works as well as the standard dose for people with cirrhosis and a type of infection called spontaneous bacterial peritonitis (SBP). It aims to see if the low dose can protect kidney function while reducing side effects and costs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old
- You have cirrhosis and have been diagnosed with SBP (spontaneous bacterial peritonitis, an infection in the belly fluid)
- You have high-risk SBP, meaning your bilirubin (a liver marker) is over 4 mg/dL or your creatinine (a kidney marker) is over 1 mg/dL at the time of diagnosis
- You have not taken any antibiotics (except norfloxacin for prevention) in the week before your SBP diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving albumin (a blood protein) in a personalized dose works better than a standard fixed dose for people with cirrhosis and sepsis-related acute kidney injury. The goal is to find a safer and more effective way to protect kidney function.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
This trial tests whether a personalized long-term albumin (a blood protein medicine) can help people with advanced liver scarring who have fluid in the belly (ascites). It compares the personalized albumin approach to standard care to see if it improves outcomes over time.
This study tests whether giving albumin (a protein) along with water pills helps reduce leg swelling in people with cirrhosis and ascites. It may be an option if your leg swelling hasn't improved with standard diuretics alone.
This study tests whether giving a common fluid (albumin) early can help protect the kidneys in people with advanced liver disease who have a sudden kidney injury. It aims to see if this simple treatment can improve recovery and prevent the need for dialysis.
This trial tests whether giving albumin through a vein is better than saline (salt water) for treating a sudden kidney injury in people with cirrhosis. The goal is to see which fluid helps the kidneys recover more effectively.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.